Thomas P Matthews

发表

The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.

Paul Workman, Edward McDonald, Chrisostomos Prodromou, 2005, Bioorganic & medicinal chemistry letters.

4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.

Mike Wood, Brian Dymock, Xavier Barril, 2007, Journal of medicinal chemistry.

Identification of inhibitors of checkpoint kinase 1 through template screening.

Ian Collins, Samantha Burns, David Williams, 2009, Journal of medicinal chemistry.

Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases.

Ian Collins, C. E. Allen, Michelle D Garrett, 2010, Bioorganic & medicinal chemistry letters.

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.

L. Pearl, X. Barril, M. Drysdale, 2008, Cancer research.

Studies on the biological activity of some nitrothiophenes.

J. O. Morley, T. Matthews, Thomas P Matthews, 2006, Organic & biomolecular chemistry.

Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing

Gary Box, Ian Collins, Isaac M. Westwood, 2011, Journal of medicinal chemistry.

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

M. Walton, N. Perkins, K. Boxall, 2015, Oncotarget.

Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies

I. Collins, T. Matthews, Alan M. Jones, 2013, Expert opinion on drug discovery.

Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors

M. Walton, K. Boxall, G. Aherne, 2012, Journal of medicinal chemistry.

Structure-based design , discovery and development of checkpoint kinase inhibitors as potential anti-cancer therapies

I. Collins, T. Matthews, Alan M. Jones, 2014 .

A fragment-based approach applied to a highly flexible target: Insights and challenges towards the inhibition of HSP70 isoforms

Ian Collins, Isaac M. Westwood, Paul Workman, 2016, Scientific Reports.

Fragment growing to retain or alter the selectivity of anchored kinase hinge-binding fragments

Ian Collins, C. E. Allen, J. Caldwell, 2014 .

Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).

S. Robinson, R. V. van Montfort, M. Lamers, 2016, Journal of medicinal chemistry.

CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

S. Robinson, M. Walton, K. Boxall, 2012, Clinical Cancer Research.

In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors.

L. Pearl, P. Workman, R. Marais, 2007, Cancer research.

Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1α Kinase-Endoribonuclease

M. Walton, R. Bayliss, L. Pickard, 2019, Journal of medicinal chemistry.

A fluorescence polarization assay for inhibitors of Hsp90.

X. Barril, M. Drysdale, P. Workman, 2006, Analytical biochemistry.

Structure-activity relationships in nitrothiophenes.

J. O. Morley, Thomas P Matthews, 2006, Bioorganic & medicinal chemistry.

Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

L. Pearl, X. Barril, M. Drysdale, 2007, Molecular Cancer Therapeutics.

Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).

R. V. van Montfort, K. Boxall, G. Aherne, 2016, Journal of medicinal chemistry.

Abstract 16602: Mitolamban is a Novel Cardiac-Enriched Mitochondrial Microprotein That Regulates Respiratory Complex III

S. Morrison, E. Olson, R. Bassel-Duby, 2020, Circulation.